ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.930
+0.010 (0.52%)
At close: Aug 17, 2026, 4:00 PM EDT
1.930
0.00 (0.00%)
After-hours: Aug 17, 2026, 6:50 PM EDT
ProQR Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 18.36 | 15.91 | 18.91 | 6.51 | 3.59 | 1.34 |
Other Revenue | 0.06 | 0.44 | 0.64 | 0.08 | 0.77 | 1.04 |
| 18.42 | 16.35 | 19.55 | 6.59 | 4.36 | 2.38 | |
Revenue Growth | 7.49% | -16.36% | 196.41% | 51.27% | 83.30% | 131.10% |
Gross Profit | 18.42 | 16.35 | 19.55 | 6.59 | 4.36 | 2.38 |
Selling, General & Admin | 15.78 | 15.06 | 13.66 | 16.24 | 18.65 | 17.37 |
Research & Development | 45.5 | 44.73 | 36.36 | 25.15 | 50.87 | 42.22 |
Operating Expenses | 61.28 | 59.79 | 50.02 | 41.38 | 69.52 | 59.59 |
Operating Income | -42.85 | -43.45 | -30.47 | -34.79 | -65.16 | -57.21 |
Interest Expense | -0.93 | -0.93 | -1.08 | -1.2 | -5.13 | -3.41 |
Interest & Investment Income | 2.33 | 2.33 | 3.25 | 2.59 | 0.11 | 0.01 |
Earnings From Equity Investments | - | - | - | - | -0.01 | -0.22 |
Currency Exchange Gain (Loss) | -0.36 | -0.36 | -0.01 | -0.26 | 4.76 | 1.51 |
Other Non Operating Income (Expenses) | -0.21 | 0.24 | 0.35 | 0.95 | 2.71 | -1.88 |
EBT Excluding Unusual Items | -42.01 | -42.17 | -27.96 | -32.7 | -62.72 | -61.2 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.51 |
Gain (Loss) on Sale of Assets | - | - | - | 3.02 | - | - |
Other Unusual Items | - | - | - | 1.87 | -1.39 | - |
Pretax Income | -42.01 | -42.17 | -27.96 | -27.81 | -64.11 | -60.68 |
Income Tax Expense | 0.03 | 0.02 | -0.2 | -0.08 | 0.1 | 0.12 |
Earnings From Continuing Operations | -42.04 | -42.18 | -27.76 | -27.74 | -64.2 | -60.8 |
Minority Interest in Earnings | - | - | - | -0.38 | -0.22 | 0.06 |
Net Income | -42.04 | -42.18 | -27.76 | -28.12 | -64.42 | -60.74 |
Net Income to Common | -42.04 | -42.18 | -27.76 | -28.12 | -64.42 | -60.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 107 | 105 | 86 | 81 | 72 | 64 |
Shares Outstanding (Diluted) | 107 | 105 | 86 | 81 | 72 | 64 |
Shares Change | 8.75% | 22.36% | 6.26% | 13.08% | 11.62% | 28.21% |
EPS (Basic) | -0.39 | -0.40 | -0.32 | -0.35 | -0.90 | -0.95 |
EPS (Diluted) | -0.39 | -0.40 | -0.32 | -0.35 | -0.90 | -0.95 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -50.16 | -53.81 | -37.81 | 20.18 | -69.22 | -26.5 |
Free Cash Flow Per Share | -0.47 | -0.51 | -0.44 | 0.25 | -0.97 | -0.41 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -232.60% | -265.77% | -155.91% | -527.60% | -1494.82% | -2405.80% |
Profit Margin | -228.18% | -258.05% | -142.05% | -426.43% | -1477.95% | -2554.25% |
Free Cash Flow Margin | -272.25% | -329.18% | -193.46% | 305.99% | -1587.89% | -1114.21% |
EBITDA | -41.9 | -42.54 | -29.58 | -34.11 | -64.38 | -56.55 |
EBITDA Margin | -227.44% | -260.26% | -151.33% | - | - | - |
D&A For EBITDA | 0.95 | 0.9 | 0.89 | 0.68 | 0.78 | 0.66 |
EBIT | -42.85 | -43.45 | -30.47 | -34.79 | -65.16 | -57.21 |
EBIT Margin | -232.60% | -265.77% | -155.91% | - | - | - |